Octubre-Diciembre 2006 N°29
ISSN 1317-987X
 
Buscar




Artículos
 
Introducción
Profilaxis
Paciente médico
Paciente quirúrgico
Paciente traumatizado
Tratamiento de TVP y EP
Situaciones especiales
Paciente pediátrico
Pacientes oncológicos
Referencias I
Referencias II



Medicina interna
II Consenso Venezolano sobre Enfermedad Tromboembólica (II): Patología Venosa

Referencias II

  1. Ullmann M, Hemmer W, Hannekum A. The urgent pulmonary embolectomy: mechanical resuscitation in the operating theatre determines the outcome. Thorac Cardiovasc Surg 1999;47:5-8.
  2. Ellis M, Manor Y, Witz M. Risk factor and management of patient with upper limb deep trombosis. Chest 2000;117:43-46.
  3. Martinelli I, Cattaneo M, Panzeri D et al. Risk factors for deep vein thrombosis of the upper extremities Ann Intern Med 1977;126:707-711.
  4. León L, Giannoukas A, Dodd D, et al. Clinical Significance of Superficial Vein Trombosis. Eur J Vasc Endovasc Surg 2005;29:10-17.
  5. Marchiori A, Verlato F, Sabbion P, et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg: a prospective, controlled, randomized study. Haematologica 2002;87:523-527.
  6. Burihan E, de Figueiredo LF, Francisco JJ, et al. Upperextremity deep venous thrombosis: analysis of 52 cases. Cardiovasc Surg 1993;1:19-22.
  7. Titon JP, Auger D, Grange P, et al. Therapeutic management of superficial venous thrombosis with calcium nadroparin: dosage testing and comparison with a non-steroidal anti-inflammatory agent. Ann Cardiol Angeiol (Paris) 1994; 43:160-166.
  8. Superficial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003;163:1657-1663.
  9. Ginsberg JS, Hirsh J, Julian J, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001; 161:2105-2109.
  10. Flessa HC, Klapstrom AB, Glueck MJ, et al. Placental transport of heparin. Am J Obstet Gynecol 1965;93:570-573.
  11. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34:557-560.
  12. Forestier F, Daffos F, Rainaut M, et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy [letter]. Thromb Haemost 1987;57:234.
  13. Blomback M, Bremme K, Hellgren M, et al. A pharmacokinetic study of dalteparin during late pregnancy. Blood Coagul Fibrinolysis 1998;9:343-350.
  14. Ginsberg JS, Hirsh J, Turner CD, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197-203.
  15. Hall JAG, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy Am J Med 1980;68:22-140.
  16. De Swiet M. Anticoagulants. Charperter 4: prescribing in pregnancy. Third edition, edited by Peter Rubin of British Medical Journal; 2000:47-64.
  17. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-1117.
  18. Wesseling J, van Driel D, Heymans HAS, et al. Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost 2001;85:609-613.
  19. Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol 1999;101:53-55.
  20. Ellison J, Walker ID, Greer IA. Antifactor Xa profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000;107: 1116-1121.
  21. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001; 108:1134-1140
  22. Gould MK, Dembitzer AD, Doyle RL, et al. Lowmolecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
  23. Bates SM, Greer IA, Hirsh J, et all. Use of Antithrombotic Agents During Pregnancy. Chest 2004;126:627S-644S.
  24. Ginsberg JS, Greer IA, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:1225-1315.
  25. Tengborn L. Recurrent thromboembolism in pregnancy and puerperium: is there a need for thromboprophylaxis? Am J Obstet Gynecol 1989;160:90-94.
  26. Brill-Edwards P, Ginsberg JS, for the Recurrence Of Clot In This Pregnancy (ROCIT) Study Group. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. N Engl J Med 2000;343:1439-1444.
  27. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-1265.
  28. McColl M, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;8:1183-1188.
  29. Middledorp S, Van der Meer J, Hamulyak K, et al. Counselling women with factor V Leiden homozygosity: use absolute instead of relative risks. Thromb Haemost 2001;87:360-361.
  30. Middledorp S, Libourel EJ, Hamulyak K, et al. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001;113:553-555.
  31. Pabinger I, Nemes L, Rintelen C, et al. Pregnancy associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000;1:37-41.
  32. Martinelli I, Legnani C, Bucciarelli P, et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-803.
  33. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997;77:39-43.
  34. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low-molecular-weight heparin ?dalteparin? in pregnancy. Thromb Res 1999;96:275-282.
  35. Gerhardt A, Scharf RE, Beckman MW, et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-380.
  36. McColl MD, Ellison J, Reid F, et al. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 2000;107:567-569.
  37. Martinelli I, de Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87:791-795.
  38. Den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia Hyperhomocysteinemia as a risk for deep-vein thrombosis. N Engl J Med 1995;334:759-762.
  39. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998;179:1324-1328.
  40. Alferivic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome. Eur J Obstet Gyencol Reprod Biol 2002;101:6-14.
  41. 340. Morrison ER, Miedzybrodzka ZH, Campbell D, et al. Prothrombotic genotypes are not associated with preeclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002;87:779-785.
  42. Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for prevention of pregnancy-induced hypertensive disease. JAMA 1991;266:260-264.
  43. CLASP Collaborative Group. CLASP: a randomized trial of low dose aspirin for the prevention and treatmet of pre-eclampisa among 9,364 pregnant women. Lancet 1994;343:619-629.
  44. Levine J. The antiphospholipid syndrome. N Eng J Med 2002;340:752-763.
  45. De Swiet M, Floyd E, Letsky E. Low risk of recurrent thromboembolism in pregnancy [letter]. Br J Hosp Med 1987;38:264.
  46. Howell R, Fidler J, Letsky E, et al. The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynecol 1983;90:1124-1128.
  47. Badaracco MA, Vessey M. Recurrent venous thromboembolic disease and use of oral contraceptives. BMJ 1974;1:215-217.
  48. Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001;185:633-637.
  49. Roberts N, Ross D, Flint SK, et al. Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. Br J Obstet Gynaecol 2001;108:327-329.
  50. Leyh RG, Fischer S, Ruhparwar A, et al. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecularweight heparin an alternative. Eur J Cardiothorac Surg 2002;21:577-579.
  51. Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and review of options for anticoagulation. J Heart Valve Dis 2002; 11:745-750.
  52. Lev-Ran O, Kramer A, Gurevitch J, et al. Low-molecularweight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000;69:264-265.
  53. Rodie VA, Thomson AJ, Stewart FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: case series. Br J Obstet Gynaecol 2002;109:1020-1024.
  54. Thomson AJ, Greer, IA. Thromboembolic disease in pregnancy and the puerperium: acute management. Royal College of Obstetricians and Gynaecologists, London. Guideline No 20, 2001. Available at: http:www.rcog.org.uk/guidelines. asp?PageID_106&GuidelineID_20). Accessed July 2003.
  55. de Valek HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med 1995;123:1-9.
  56. Fernández-Pavón A, Fontcuberta J, Nabarro JL y col. Mesa redonda Terapéutica Anticoagulante. Temas en controversia. Rev Iberoamer Tromb Hemostasi 1996;9:155-159.
  57. de Veber G, Andrew M. Cerebral sinovenous thrombosis in Children's. Engl J Med 2001;345:417-423.
  58. Monagle P, Chan A, Chalmers E, et al. Antitrombotic Therapy in Children. Chest 2004;126:645-687.
  59. Guideline. The investigation and Management of neonatal haemostasis and Trombosis. British Journal of Haematology 2002;119:295-309.
  60. Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8-21.
  61. Rick M, Walsh C, Key N. Congenital Bleeding Disorders. Hematology 2003:559-574.
  62. Sutor AH, Severing T. Heparin induced thrombocytopenia in pediatrics. Semin Tromb Hemost 2001;27:293-299.
  63. Andres M, Michelson AD, Bowill T, et al. The prevention and treatment of thromboembolic disease in children: a need for trombophilia programs. Pediatry Hematol Oncol 1997;19:7-22.
  64. Massicotte P, Adams M, Marzinotto V, Brooker L. Low Molecular weight heparin in pediatric patient's whith trombotic disease: a dose finding study. Journal of Paediatrics 1996;128:313-318.
  65. Sutor AH, Massicotte P,Leaker M, Andrew M. Heparin Therapy in Pediatric Patients. Seminars in Thrombosis and haemostasis 1997;23:303-319.
  66. Ginsberg J, Crowther M, White R. Anticoagulation Therapy. Hematology 2001:339-354.
  67. Severing T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001;27:293-299.
  68. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol 1973; 46:548-550.
  69. Schmugge M, Risch L, Huber A, et al. Heparin induced thrombocytopenia associated throombosis in pediatric intensive care patients. Pediatrics 2002; 109-110.
  70. Kuhle S, Massicotte MP, Andrew M, et al. A dose-finding study of tinzaparin in pediatric patients. Blood 2002;100:279.
  71. Israels SJ, Cheang T, McMillan-Ward EM, et al. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer. J Pediatr 2001;138:116-119.
  72. Ansell J, Weitz J, Comerota A. Advances in therapy and management of Antitrombotic drugs for venous thromboembolism. Hematology 2000:266-279.
  73. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
  74. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1968. Br J Surg 1991;78:849-852.
  75. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg 1992; 127:310-313.
  76. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 1997;78:126-132.
  77. Kakkar AK, Williamson RCN. Prevention of venous thromboembolism in cancer patients. Semin Thromb Haemost 1999;25:239-243.
  78. Wille-Jorgensen P, Rasmussen MS, Andersen BR, et al. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev (database online). Issue 1,2003.
  79. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.
  80. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev 2002;28:141-144.
  81. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-920.
  82. Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107(I):17-21. 409.
  83. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889.
  84. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
  85. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131.
  86. Arkel YS. Thrombosis and cancer. Semin Oncol 2000;27:362-374.
  87. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine 1999;78:285-291.
  88. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87:575-579.
  89. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87:1076-1077.
  90. Kakkar AK, Haas S, Walsh D, et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery [abstract]. Thromb Haemost 2001;86(suppl):OC1732.
  91. Rajan R, Gafni A, Levine M, et al. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995;13:42-46.
  92. Bergqvist D. Venous thromboembolism and cancer: prevention of VTE. Thromb Res 2001;102(V):209-213.
  93. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
  94. Becker J, Borgstrom S, Saltzman GF. Occurrence and course of thrombosis following prostatectomy: a phlebographic investigation. Acta Radiol Diagn (Stockh) 1970;10:513-533.
  95. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 1999;25:147-155.
  96. Randolph AG, Cook DJ, Gonzales CA, et al. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 1998;113:165-171.
  97. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990;112:423-428.
  98. Couban S, Goodyear M, Burnell M, et al. A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheterassociated thrombosis in patients with cancer [abstract]. Blood 2002;100(suppl):703a.
  99. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med 2002;32:84-88.
  100. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
  101. Reichardt P, Kretzschmar A, Biakhov M, et al. A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters [abstract]. Clin Oncol 2002;21:abstract 1474.
  102.  Lopez J, Kearon C, Lee A. Deep Venous Thrombosis in Hematology 2004 of American Society of Hematology Education Program Book. San Diego; 2004: 439-456.
  103. Kakkar AK, Levine MN, Prandoni P, Lee AY, et al. What is the role for antithrombotics in cancer care?: Interactive session with panel discussion. Cancer Treatments Reviews 2002;28:157-159.
  104. Horlocker T.T, Wedel DJ, Benzon H, et al. Defining the Risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation) Reg Anesth Pain Med 2003;28:172-197.
  105. Horlocker T.T, Wedel DJ, Benzon H, et al. Regional Anesthesia in the Anticoagulated Patient: Defining the Risks. Reg Anesth Pain Med 2004;29:1-11.
  106. Mateo J, Oliver A, Borrell M, et all. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study or Thrombophilia (EMET Study). Blood Coag Fibrinol 1998;9:71-78.
  107. Souto JC, Almasy L, Borrel M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT Study. Am J Hum Genet 2000;67:1452-1459.
  108. Bates SM, Greer IA, Hirsh J, et al. Use of Antithrombotic Agents During Pregnancy. Chest 2004;126:627S-644S.
  109. Corral J, Gonz_lez-Conejero R y Vicente V. Variabilidad polim_rfica en el sistema hemost_tico: efecto en trombosis, hemorragia y farmacogen_tica. Haematol_gica 2002;87(1):307-312.
  110. Kupferminc M, Eldor A, Steinman N, et al. Increased frequency or Genetic Thrombophilia in Women with complications of pregnancy. N Engl J Med 1999;340:9-13.
  111. Weitz JI, Middeldorp S, and Heit JA. Thrombophilia and New Anticuagulant Drugs. American Society of Hematology Education Program Book December, 2004:425-426.
Introducción
Profilaxis
Paciente médico
Paciente quirúrgico
Paciente traumatizado
Tratamiento de TVP y EP
Situaciones especiales
Paciente pediátrico
Pacientes oncológicos
Referencias I
Referencias II

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit